Jan 09, 2023 8:00am EST Anebulo Pharmaceuticals Announces Completion of Dosing and Preliminary Data from Part B of its Phase 2 Study of ANEB-001 for Acute Cannabinoid Intoxication
Nov 10, 2022 8:00am EST Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2023 Financial Results and Recent Updates
Nov 01, 2022 4:00pm EDT Anebulo Pharmaceuticals Announces Appointment of Nat Calloway, Ph.D., to Board of Directors
Sep 26, 2022 7:00am EDT Anebulo Pharmaceuticals Announces Positive Interim Data for ANEB-001 from Part B of its Phase 2 Clinical Trial for Acute Cannabinoid Intoxication
Sep 09, 2022 8:00am EDT Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Highlights Recent Business Progress
Aug 23, 2022 5:00pm EDT Anebulo Pharmaceuticals to Host Inaugural R&D Day in New York City on Monday, September 26
Jul 05, 2022 6:00am EDT Anebulo Pharmaceuticals Announces Positive Topline Data for ANEB-001 from a Phase 2 Clinical Trial for Acute Cannabinoid Intoxication
Jun 23, 2022 4:00pm EDT Anebulo Pharmaceuticals to Announce Topline Data for ANEB-001 from an Ongoing Phase 2 Clinical Trial for Acute Cannabinoid Intoxication on Tuesday July 5, 2022
